Kazia Therapeutics (KZIA) Shares Outstanding (Weighted Average) (2009 - 2025)

Kazia Therapeutics has reported Shares Outstanding (Weighted Average) for 15 years, with the latest figure at $122.5 million in Q4 2025.

• For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 7618416.1% year-over-year to $122.5 million; the trailing twelve-month figure through Dec 2025 stood at $122.5 million (up 7618416.1% YoY), and the FY2025 full-year result was $78.8 million, up 17.65% from the prior year.
• Shares Outstanding (Weighted Average) for Q4 2025 stood at $122.5 million, up from $78.8 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $122.5 million in Q4 2025, with the low at $1608.1 in Q4 2024.
• Historically, Shares Outstanding (Weighted Average) has averaged $53.4 million across 5 years, with a median of $66.1 million in 2023.
• Annual changes were most pronounced in 2021 — Shares Outstanding (Weighted Average) slumped 99.99% — and 2025, when it soared 7618416.1%.
• Kazia Therapeutics' Shares Outstanding (Weighted Average) stood at $7285.0 in 2021, then decreased by 15.88% to $6128.0 in 2022, then sank by 60.91% to $2395.6 in 2023, then slumped by 32.87% to $1608.1 in 2024, then soared by 7618416.1% to $122.5 million in 2025.
• The last three Shares Outstanding (Weighted Average) figures came in at $122.5 million (Q4 2025), $78.8 million (Q2 2025), and $1608.1 (Q4 2024), per Business Quant data.